Ultragenyx Pharmaceutical Inc. (RARE)

22.48 -1.68 (-6.95%)

As of 2026-05-19 14:59:59 EST

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

Traded asNasdaq: RARE
ISINUS90400D1081
CIK0001515673
LEI529900EV44GVDN1DCX77
EIN272546083
SectorBiotechnology
IndustryPharmaceutical Preparations
CEO—
Employees893
Fiscal Year End1231
Address60 LEVERONI COURT, NOVATO, CA, 94949
Phone415-483-8800
Websitehttp://ultragenyx.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
RAREUltragenyx Pharmaceutical Inc.2026-05-19 14:59:5922.48-1.68-6.95
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
RARE0001515673Ultragenyx Pharmaceutical Inc.US90400D1081529900EV44GVDN1DCX77272546083Nasdaq2834Pharmaceutical Preparations1231DE60 LEVERONI COURTNOVATOCA94949UNITED STATESUS415-483-880060 LEVERONI COURT, NOVATO, CA, 9494960 LEVERONI COURT, NOVATO, CA, 94949—Biotechnology2010—893http://ultragenyx.com3,400,000,00072,174,30798,489,224Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.2026-05-14 16:47:52
This is a preview of the latest data. Subscribe to access the full data.
RARE Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
RARE Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20253,400,000,000-300,000,000-8.108196,629,7884,128,6624.4634
20243,700,000,000600,000,00019.354892,501,12610,165,43912.3463
20233,100,000,000-200,000,000-6.060682,335,68712,118,99817.2594
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Eric CrombezChief Medical Officer, Executive Vice President2025630,23102,407,560238,12514,0004,002,173
Karah ParschauerExecutive Vice President, Chief Legal Officer2025585,34202,075,430220,53014,0003,509,313
Howard HornChief Financial Officer, Executive Vice President2025604,38502,241,463227,62514,0003,750,607
Erik HarrisChief Commercial Officer, Executive Vice President2025619,69202,407,560291,56314,0004,045,072
Emil D. KakkisChief Executive Officer, President2025861,10008,364,938299,66332,47811,405,535
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20251,371
20241,294
20231,276
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue673,000,000560,230,000434,249,000
Cost Of Revenue109,000,00076,728,00045,209,000
Gross Profit564,000,000483,502,000389,040,000
Research And Development Expenses750,000,000697,865,000648,449,000
General And Administrative Expenses349,000,000321,610,000309,799,000
Operating Expenses1,099,000,0001,019,475,000958,248,000
Operating Income-535,000,000-535,973,000-569,208,000
Net Income-575,000,000-569,183,000-606,639,000
Earnings Per Share Basic-5.83-6.29-8.25
Earnings Per Share Diluted-5.83-6.29-8.25
Weighted Average Shares Outstanding Basic98,600,00090,538,11873,543,862
Weighted Average Shares Outstanding Diluted98,600,00090,538,11873,543,862
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents421,000,000173,729,000213,584,000
Marketable Securities Current259,000,000436,296,000363,625,000
Accounts Receivable158,000,000121,801,00073,390,000
Inventories52,000,00045,007,00033,969,000
Non Trade Receivables1,000,0001,800,0001,100,000
Other Assets Current61,000,00040,290,00047,616,000
Total Assets Current951,000,000817,123,000732,184,000
Marketable Securities Non Current57,000,000135,004,000199,901,000
Property Plant And Equipment244,000,000265,929,000290,566,000
Other Assets Non Current60,000,00062,680,00057,685,000
Total Assets Non Current581,000,000686,333,000758,829,000
Total Assets1,532,000,0001,503,456,0001,491,013,000
Accounts Payable31,000,00038,756,00042,114,000
Deferred Revenue———
Short Term Debt———
Other Liabilities Current7,000,0004,280,000196,486,000
Total Liabilities Current384,000,000344,153,000280,437,000
Long Term Debt———
Other Liabilities Non Current20,000,00017,082,00012,205,000
Total Liabilities Non Current1,221,000,000897,006,000935,162,000
Total Liabilities1,605,000,0001,241,159,0001,215,599,000
Common Stock092,00082,000
Retained Earnings-4,532,000,000-3,956,844,000-3,387,661,000
Accumulated Other Comprehensive Income1,000,000-643,000647,000
Total Shareholders Equity-80,000,000255,297,000275,414,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization35,000,00035,543,00026,006,000
Share Based Compensation Expense———
Other Non Cash Income Expense2,000,0003,489,000-2,300,000
Change In Accounts Receivable31,000,00033,598,00022,778,000
Change In Inventories6,000,00011,207,0006,930,000
Change In Non Trade Receivables———
Change In Other Assets——-15,325,000
Change In Accounts Payable———
Change In Other Liabilities———
Cash From Operating Activities-466,000,000-414,188,000-474,806,000
Purchases Of Marketable Securities186,000,000408,613,000526,382,000
Sales Of Marketable Securities03,247,00050,672,000
Acquisition Of Property Plant And Equipment6,000,0007,491,00044,267,000
Acquisition Of Business—00
Other Investing Activities1,000,0002,436,0005,048,000
Cash From Investing Activities236,000,000-17,768,000168,000,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock0862,0008,415,000
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities00-28,000
Cash From Financing Activities478,000,000399,241,000388,142,000
Change In Cash252,000,000-35,240,00081,798,000
Cash At End Of Period421,000,000173,729,000213,584,000
Income Taxes Paid4,000,000——
Interest Paid———
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-5.83-6.29-8.25
Price To Earnings Ratio-3.9451-6.6884-5.7964
Earnings Growth Rate-7.3132-23.7576-18.4783
Price Earnings To Growth Ratio0.53950.28150.3137
Book Value Per Share-0.74042.89713.7449
Price To Book Ratio-31.065814.521512.7694
Ebitda-536,000,000-533,640,000-580,633,000
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures13,071,00010,906,00056,846,000
Free Cash Flow-479,071,000-425,094,000-531,652,000
Return On Equity7.1875-2.2295-2.2026
One Year Beta0.97670.95861.2199
Three Year Beta1.02941.12461.1498
Five Year Beta1.0831.11851.1859
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
SULIMAN SHEHNAAZDirector2026-05-185,740D27,951
Dunsire DeborahDirector2026-05-147,751A38,566
Dunsire DeborahDirector2026-05-1414,058A14,058
WELCH DANIEL GDirector2026-05-147,751A40,441
WELCH DANIEL GDirector2026-05-1414,058A14,058
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Gilbert Cisneros2026-04-07CA31Purchase2026-03-03—$1,001 - $15,000
Gilbert Cisneros2026-03-09CA31Purchase2026-02-18—$1,001 - $15,000
Gilbert Cisneros2025-09-12CA31Purchase2025-08-08—$1,001 - $15,000
Gilbert Cisneros2025-08-14CA31Purchase2025-07-15—$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM2026-03-312,192,418104,65020.95
BANK OF AMERICA CORP /DE/2026-03-3121,925,1271,046,54620.95
ADAGE CAPITAL PARTNERS GP, L.L.C.2026-03-3110,056,000480,00020.95
ALLIANCEBERNSTEIN L.P.2026-03-31644,57528,02523
AMERICAN CENTURY COMPANIES INC2026-03-31456,29121,78020.95
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
RUSSELL INVESTMENT FUNDS2026-03-31U.S. Strategic Equity FundRIFAX19,517408,881.150.0685
RUSSELL INVESTMENT FUNDS2026-03-31U.S. Small Cap Equity FundRIFBX5,917123,961.150.0596
M FUND INC2026-03-31M Capital Appreciation FundMFCPX39,179820,800.050.3125
Meeder Funds2026-03-31Adviser ClassSRUAX-7,156-149,918.2-0.062
Meeder Funds2026-03-31Institutional ClassSRUIX-7,156-149,918.2-0.062
This is a preview of the latest data. Subscribe to access the full data.